Peptides DB
Research-centric peptide and protocol reference hub
Study 33 of 38SS-31 literatureMethodsX · Observational2026

Assessing health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia.

The study developed a culturally relevant tool to assess health beliefs related to breast cancer patient delay in West Sumatra, showing good internal consistency.

Read at MethodsXAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
4
Preclinical
26
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study evaluated health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia, using a 31-item questionnaire based on the Health Belief Model. The study involved 250 breast cancer patients and aimed to understand the connection between health beliefs and delays in diagnosis and treatment. The final tool demonstrated good internal consistency with a Cronbach's α ranging from 0.809 to 0.871.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Cronbach's α: 0.809-0.871 for the final tool.2026

Abstract

The authors’ words, as MethodsX supplied them

Delays in receiving a breast cancer (BC) diagnosis and treatment continue to be a major public health concern, particularly in environments where financial status, cultural values, and religious beliefs have a significant impact on how individuals react to disease. However, there are still few established, culturally appropriate instruments for assessing Health Belief Model (HBM) constructs and comprehending how they contribute to patient delay. In this study, a protocol for evaluating HBM components and investigating their connection to patient delay among patients with BC in West Sumatra, Indonesia, is presented. A 31-item questionnaire encompassing six HBM domains: perceived risk, severity, benefits, barriers, self-efficacy, and cues to action was used to gather data from 250 BCE patients in this cross-sectional study. Exploratory factor analysis revealed five meaningful latent constructs, and one poorly performing item was removed to strengthen the instrument. Good internal consistency was shown by the final tool (Cronbach's α: 0.809-0.871). Associations between HBM components and patient delay were then examined through logistic regression using crude and adjusted models. The protocol proved practical and feasible in a community setting.

Elsewhere in the SS-31 corpus

CStructural and functional characterisation of the dextran utilisome from <i>Bacteroides thetaiotaomicron</i>.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.reviewBKidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.Renal failure · 2026 · 35.7% of participants had moderate-to-high KDIGO renal risk.HumanBAssociation of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.Annals of medicine · 2026 · Higher BMR was associated with reduced prevalence of all-cause mortality in older survivors aged ≥60 years.HumanBDiagnostic performance of Xpert MTB/RIF Ultra assay for tuberculosis in stool specimens among adult presumptive TB patients in a generalized HIV epidemic settingbiorxiv-preprint · 2026 · Sensitivity of Xpert-Ultra assay in stool specimen was 90.32% (95% CI, 74.25% to 97.96%)Human